Investor Presentaiton
Corporate overview
4DMedical is a software company creating a step change in the capacity of physicians to diagnose and manage
patients with lung disease via its four-dimensional lung imaging platform - XV TechnologyⓇ
•
Focused on commercialising our flagship XV Lung Ventilation Analysis software (XV LVASⓇ), which utilises
mathematical models and algorithms to convert X-ray images into quantitative scan data.
Clinically validated to provide real-time, non-invasive analysis of regional lung motion and airflow analysis.
The global respiratory diagnostic market represents - USD $31.3¹ billion per annum opportunity
Approximately 378 million respiratory diagnostic tests are performed per annum globally.
Existing lung diagnostics are decades out of date, not fit for purpose and ripe for displacement.
Initial focus on the U.S. respiratory diagnostic market worth USD $13.7 billion per annum.
The Company is well funded to execute on commercialisation strategy
•
Offering is focused on improving hospital and patient outcomes with limited CAPEX requirements.
Globally recognised
U.S hospital customers
and collaborators
72
Global Patents
4DMedical™
Technology
conceived 2005
Incorporation
Melbourne 2012
SaaS
Model
Capital light business model with rapid SaaS deployment - expected > 90% gross margins margin.
First mover advantage with a robust IP portfolio and advanced product pipeline present significant entry barriers.
Strong balance sheet of AUD $51.1 million as at 30 June 2022 and zero debt.
USD $31.3 billion
global market
opportunity
4DMedical Limited (ASX:4DX) Investor Presentation | September 2022
1. Frost and Sullivan Report 2020, USD $31.3 billion global spend annually.
2. Frost and Sullivan Report 2020, 378 million procedures are performed annually
3View entire presentation